Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ATF4 | P18848 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595768 | 0.93 | L3MBTL1 (0.58) | LMNAGAAPTGS2CYP1A2CYP3A4 | |
| SCHEMBL10622944 | 0.88 | MAPT (0.57) | LMNAGAAPTGS2SMN1; SMN2NPC1 | |
| SCHEMBL3913180 | 0.86 | PTGS2 (0.60) | PTGS2CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL5120243 | 0.82 | PTGS2 (0.81) | LMNAPTGS2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29240035 | 0.82 | PTGS2 (0.57) | PTGS2CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL11562520 | 0.82 | PTGS2 (0.57) | PTGS2CYP1A2CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL9363100 | 0.82 | PTPN7 (0.64) | PTGS2SMN1; SMN2POLBNPC1TDP1 | |
| SCHEMBL9313367 | 0.82 | GAA (0.61) | LMNAGAANPC1TDP1L3MBTL1 | |
| SCHEMBL1244295 | 0.81 | KMT2A (0.54) | LMNAPTGS2SMN1; SMN2ATF4TDP1 | |
| SCHEMBL11440981 | 0.81 | MAPT (0.60) | LMNAPTGS2CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199523-A1 | Heterocyclic calcium in channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2003-10-23 | — | — | US | disclosed |
| US-4008324-A | Phenoxyalkylcarboxylic acid salt of 1-cinnamyl-4-diphenylmethyl piperazine, method of preparation and antihypercholesteremic | LUDWIG MERCKLE KG (DT) | 1977-02-15 | — | — | US | disclosed |
| US-3714362-A | ACETIC ACID DERIVATIVES AS HYPOLIPIDEMICS | SANDOZ AG | 1973-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199523-A1 | Heterocyclic calcium in channel blockers | CACNA1C, CACNA1B, CACNA1D | LMNA 1108/4885GAA 2254/4885PTGS2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.